학술논문
Use of Extracorporeal Photopheresis (ECP) in the Treatment of Patients with Cutaneous T-Cell Lymphoma (CTCL), 2010-2015
Document Type
Article
Author
Source
Blood; December 2017, Vol. 130 Issue: 1, Number 1 Supplement 1 p4093-4093, 1p
Subject
Language
ISSN
00064971; 15280020
Abstract
Introduction: Extracorporeal photopheresis (ECP) is an immunotherapeutic procedure approved in the US for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL); in Europe, ECP is also used for the treatment of additional conditions such as graft versus host disease (GvHD), organ transplant rejection, and selected autoimmune diseases. Developments in immune system/cell biology and publications of real-world ECP data have advanced the understanding of the effects of ECP as a cell-based immunomodulator. The National Comprehensive Cancer Network (NCCN) CTCL Treatment Guidelines as well as the European Organization for Research and Treatment of Cancer (EORTC) recommend ECP as systemic therapy, which can be used in combination with interferon and/or a retinoid. The objective of this study was to analyze real-world use of ECP in the treatment of patients with CTCL in the US between 2010 and 2015.